Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | APLNR | P35414 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468292 | 0.82 | CYP19A1 (0.52) | MKNK1MKNK2MEN1PDGFRBPDGFRA | |
| SCHEMBL21076869 | 0.81 | MKNK1 (0.66) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL18262925 | 0.79 | AURKA (0.45) | MEN1PDGFRBPDGFRAMAPK1KDM4E | |
| SCHEMBL15791319 | 0.79 | APLNR (0.47) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL4416926 | 0.78 | MAPT (0.45) | MAPK1KDM4EHSD17B10HTTNPC1 | |
| SCHEMBL2652791 | 0.78 | MKNK1 (0.55) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL26260092 | 0.76 | NPC1 (0.60) | MKNK1MKNK2MEN1PDGFRBPDGFRA | |
| SCHEMBL519862 | 0.75 | HSD17B10 (0.65) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL10208603 | 0.75 | MKNK1 (0.59) | MKNK1MKNK2MEN1PSIP1AXL | |
| SCHEMBL7085711 | 0.74 | MKNK1 (0.55) | MKNK1MKNK2PDGFRBPDGFRAAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2009-08-27 | — | — | US | disclosed |
| EP-2023919-A2 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | Molecular Neuroimaging, LLC (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008118122-A2 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1910315-A2 | BENZODIAZEPINE DERIVATIVES, THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007026254-A2 | BENZODIAZEPINE DERIVATIVES , THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF | NEURO3D (FR) | 2007-03-08 | — | — | WO | disclosed |
| EP-1749824-A1 | Benzodiazepine derivatives, their preparation and the therapeutic use thereof | NEURO3D (FR) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215752-A1 | Compounds, preparation and therapeutic use thereof | PDE12, PDE4B, PDE2A | MKNK1 4437/4885MKNK2 3862/4885MEN1 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.